The chapter

Population-scale precision medicine depends on turning biological insight into interventions that are safe, manufacturable, and regulator-ready while adapting to genotype, phenotype, exposures, and disease state. As of 2026, mRNA is a validated prophylactic platform and is expanding into oncology and other therapeutics, but progress is limited by delivery and dosing precision in heterogeneous patients. Circular RNA is being explored to tune stability and expression duration. Continued evidence synthesis on COVID-19 mRNA vaccines keeps refining mechanisms and safety, underscoring surveillance and interpretability for real-world deployment.

This record lists the chapter's canonical sources and its revisions as recorded on Comuvia's BookWriter and MediaManager systems. The chapter and its video are AI-authored and AI-produced; the sources ground the text, they do not endorse it.

Chapter 77. Therapeutics, Vaccines, and Precision Medicine at Scale — chapter poster

Sources

The chapter's canonical source pack as recorded on BookWriter: milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers. Tier reflects citation strength, not Comuvia's endorsement.

#TypeSourceTierFound via
1PaperThe CRISPR Patent Ruling and Implications for Medicine
Paradise, Jordan · JAMA · 2023 · doi:10.1001/jama.2022.24986
gold · highly citedcrossref
2PaperThe “All of Us” Research Program
New England Journal of Medicine · 2019 · doi:10.1056/nejmsr1809937
gold · highly citedcrossref
3PaperApplication of mRNA Technology in Cancer Therapeutics
Eralp, Yesim · Vaccines · 2022 · doi:10.3390/vaccines10081262
strongcrossref
4PaperCircular RNA Therapeutics and Vaccines
Liu, Xiang et al. · Trends in mRNA Vaccine Research · 2024 · doi:10.1002/9783527838394.ch5
strongcrossref
5PaperFrom Rejection to Revolution: mRNA Vaccines Go Beyond Infections to Diseases in the Brain
Grinstein, Jonathan D. · Inside Precision Medicine · 2025 · doi:10.1089/ipm.12.03.11
strongcrossref
6PapermRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework
Niazi, Sarfaraz K. · RSC Pharmaceutics · 2026 · doi:10.1039/d5pm00159e
strongcrossref
7PapermRNA Vaccine Technology Beyond COVID-19
Oloruntimehin, Sola et al. · Vaccines · 2025 · doi:10.3390/vaccines13060601
strongcrossref
8PapermRNA vaccines
Hillery, Anya M · mRNA Therapeutics · 2025 · doi:10.1016/b978-0-443-28934-7.00009-1
strongcrossref
9PaperEvidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines
Sohn, Woo Yun et al. · Vaccine · 2026 · doi:10.1016/j.vaccine.2026.128394
strongcrossref
10PapermRNA Therapeutics Beyond Vaccines: A Platform Technology for Cancer, Autoimmune, and Genetic Disorders
Obi, Obi Blessing · 2026 · doi:10.2139/ssrn.6141686
strongcrossref
11PapermRNA vaccines for COVID-19
Hillery, Anya M · mRNA Therapeutics · 2025 · doi:10.1016/b978-0-443-28934-7.00005-4
strongcrossref
12PapermRNA Innovates the Vaccine Field
Pardi, Norbert · Vaccines · 2021 · doi:10.3390/vaccines9050486
strongcrossref

Revisions

WhenEventDetail
May 5, 2026Source pack versionversion 1 · refresh coverage gap · 12 entries
May 6, 2026Source checkpass · coverage 100 %
Aug 27, 2026Upload (full)uploaded · YaymCkLRSJU
Aug 27, 2026Upload (short_15s)uploaded · 9UnqMroGZlQ
Sep 2, 2026Published on the channelupload date as listed on the channel · Ilv748CRkwo

About this record

Book: The Long Horizon: A Vision of Frontier Technology from 2026 to 2400 (BookWriter (Comuvia S2)). Channel: Comuvia Vision. Sources are the chapter's canonical source pack in BookWriter (milestone papers, patents and news found through Crossref, OpenAlex, USPTO and news providers; tiers gold/strong by citation strength); revisions are the pack versions, the compliance checks and the campaign's uploads. The chapter text itself is AI-authored on BookWriter; the sources ground it, they do not endorse it.

anchor 3c4d523c-ac7f-4dfd-935c-2d9464d5e3a9 · thread 65baf87d-0fa5-4a7e-9f21-d155ab0f7de4